Cobra Enters Manufacturing Agreement with GenVec

February 12, 2008
BioPharm International Editors

Cobra Biomanufacturing Plc (Keele, UK) has entered into a manufacturing development agreement with GenVec, Inc. (Gaithersburg, MD) for TNFerade.

Cobra Biomanufacturing Plc (Keele, UK) has entered into a manufacturing development agreement with GenVec, Inc. (Gaithersburg, MD) for TNFerade. The agreement will cover technology transfer, scale-up, and validation of the manufacturing process for TNFerade through cGMP consistency lots that will be produced at Cobra's facility in Oxford, United Kingdom.

TNFerade is an adenovector, which contains the gene for tumor necrosis factor- alpha, an immune system protein with potent and well-documented anticancer effects, for direct injection into tumors. TNFerade is being developed for use in combination with radiation or chemotherapy for the treatment of various cancers.

Cobra Biomanufacturing releaseGenVec release (PDF)

Related Content:

News